CRBP Corbus Pharmaceuticals announces FDA clearance to initiate tempo-1 registrational study of crb-701 in patients with 2l oropharyngeal ca

CRBP Corbus Pharmaceuticals announces FDA clearance to initiate tempo-1 registrational study of crb-701 in patients with 2l oropharyngeal cancer Corbus Pharmaceuticals announces FDA clearance to initiate tempo-1 registrational study of crb-701 in patients with 2l oropharyngeal cancer Corbus Pharmaceuticals holdings Inc: expects to initiate enrollment in tempo-1 in September 2026